BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34534136)

  • 1. Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells.
    Kawano T; Tsuyuki Y; Suzuki Y; Shimada K; Kato S; Takahara T; Mori M; Nakaguro M; Sakakibara A; Nakamura S; Satou A
    Am J Surg Pathol; 2021 Dec; 45(12):1606-1615. PubMed ID: 34534136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological analysis of neoplastic PD-L1-positive EBV
    Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
    Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reappraisal of Primary Epstein-Barr Virus (EBV)-positive Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract: Comparative Analysis Among Immunosuppressed and Nonimmunosuppressed Stage I and II-IV Patients.
    Miyagi S; Ishikawa E; Nakamura M; Shimada K; Yamamura T; Furukawa K; Tanaka T; Mabuchi S; Tsuyuki Y; Kohno K; Sakakibara A; Satou A; Kato S; Fujishiro M; Nakamura S
    Am J Surg Pathol; 2020 Sep; 44(9):1173-1183. PubMed ID: 32349049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
    Ozsan N; Cagirgan S; Saydam G; Gunes A; Hekimgil M
    Pathol Res Pract; 2013 Aug; 209(8):471-8. PubMed ID: 23726928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
    Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed cell death-ligand 1 (PD-L1)
    Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
    Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
    Xue T; Wang WG; Zhou XY; Li XQ
    Pathology; 2018 Dec; 50(7):725-729. PubMed ID: 30389217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of EBV-encoded small RNA targeted PCR to classify EBV positive diffuse large B-cell lymphoma (DLBCL) of the elderly.
    Lee J; Park M; Lee MH; Woo HJ; Kim HW; Yang JY; Eom YB; Kim SH; Yoo C; Kim JB
    Int J Clin Exp Pathol; 2015; 8(7):7859-68. PubMed ID: 26339350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.
    Park S; Lee J; Ko YH; Han A; Jun HJ; Lee SC; Hwang IG; Park YH; Ahn JS; Jung CW; Kim K; Ahn YC; Kang WK; Park K; Kim WS
    Blood; 2007 Aug; 110(3):972-8. PubMed ID: 17400912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 13. Epstein-Barr Virus-Positive Diffuse Large B cell Lymphoma in the Experience of a Tertiary Medical Center in Poland.
    Ziarkiewicz M; Wołosz D; Dzieciątkowski T; Wilczek E; Dwilewicz-Trojaczek J; Jędrzejczak WW; Gierej B; Ziarkiewicz-Wróblewska B
    Arch Immunol Ther Exp (Warsz); 2016 Apr; 64(2):159-69. PubMed ID: 26084760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
    Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
    Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
    Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
    Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients.
    Okamoto A; Yanada M; Inaguma Y; Tokuda M; Morishima S; Kanie T; Yamamoto Y; Mizuta S; Akatsuka Y; Yoshikawa T; Mizoguchi Y; Nakamura S; Okamoto M; Emi N
    Hematol Oncol; 2017 Mar; 35(1):87-93. PubMed ID: 26177728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group.
    Shen Z; Hu L; Yao M; He C; Liu Q; Wang F; Gu W; Wang Y; Dong M; Zhu T; Yin T; Li F; Jin Y; Huang S; Zhang H; Sang W;
    Int J Cancer; 2022 Jan; 150(2):327-334. PubMed ID: 34520566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein Barr Virus Infection Can be a Secondary Event in B-Cell Lymphomas: A Review of 338 Cases and a Novel Finding of Zonal EBER+ Tumor Cells Showing Features of Progression From Underlying EBV-negative Lymphoma.
    Miller IJ
    Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):165-173. PubMed ID: 28800008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
    Cho J; Kim E; Yoon SE; Kim SJ; Kim WS
    Cancer; 2023 May; 129(10):1502-1512. PubMed ID: 36812290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
    Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
    Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.